A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 30, 2024

Primary Completion Date

February 1, 2025

Study Completion Date

May 30, 2025

Conditions

Uncomplicated MalariaAsymptomatic ConditionFalciparum Malaria

Interventions

DRUG

ZY19489 + Ferroquine (FQ)

ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h.

DRUG

Placebo

ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h.

Trial Locations (1)

RECRUITING

Centre de Recherches Médicales de Lambaréné, Lambaréné

All Listed Sponsors

lead

Zydus Lifesciences Limited

INDUSTRY